Drugs Channel
Topics & Medications
Quicklinks
Related Channels

Pomalidomide

Important Information for Your Healthcare Provider

You should talk with your healthcare provider prior to taking this medication if you:
 
  • Have liver disease, such as hepatitis, cirrhosis, or liver failure
  • Have kidney disease, such as kidney failure (renal failure)
  • Have had a blood clot in your lungs or veins
  • Have had a serious rash from taking thalidomide (Thalomid®) or lenalidomide (Revlimid®
  • Smoke cigarettes
  • Have neuropathy (nerve damage that causes numbness and pain in the hands and feet)
  • Have any allergies, including to foods, dyes, or preservatives.
 
Also, let your healthcare provider know if you are:
   
Make sure to tell your healthcare provider about all other medications you are taking, including prescription and nonprescription medicines, vitamins, and herbal supplements.
 
(Click Precautions and Warnings With Pomalidomide to learn more, including information on who should not take the drug.)
 

Clinical Effects for Pomalidomide

Pomalidomide has been studied in clinical trials that included people with multiple myeloma whose cancer progressed during or soon after treatment with another multiple myeloma medicine. In one study, 7.4 percent of people who had failed other treatment responded at least partially to pomalidomide. When pomalidomide was used in combination with dexamethasone (Decadron®, Dexpak®, Maxidex®), 29.2 percent responded. People continued to respond to treatment for a median of 7.4 months (the median is the middle number of a group of numbers).
 
5 Easy Tips to Manage Visitors During Cancer Treatment

Pomalidomide Drug Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.